Med2Date — Clinical Guidelines
Home Neurology Neurologic Complications of Systemic Disease

Neurologic Complications of Systemic Disease

Last updated 14 May 2026 · Systemic disease
🎧 Neurologic Complications of Systemic Disease — deep-dive podcast

📋 Key Information Summary

📋
  • Neurologic complications of systemic disease are common in Australian practice and require early recognition to prevent irreversible damage.
  • Diabetic peripheral neuropathy affects up to 50 % of people with long-standing diabetes; annual monofilament testing (10 g Semmes-Weinstein) is the recommended screening tool in primary care (MBS Item 2517/721 for GP Management Plans).
  • Diabetic autonomic neuropathy increases mortality—screen for cardiovascular autonomic neuropathy (CAN) using lying-to-standing BP and heart rate variability at diagnosis of type 2 diabetes and 5 years after type 1 diabetes onset.
  • Focal diabetic mononeuropathies (cranial nerve III, VI, VII; peripheral nerve palsies) are generally self-limiting over 3–6 months but require exclusion of compressive or ischaemic causes (urgent neuroimaging if atypical features).
  • Painful diabetic neuropathy: first-line agents are amitriptyline, duloxetine, or pregabalin; gabapentin and tramadol are second-line. All are PBS-listed for neuropathic pain.
  • Hepatic encephalopathy (HE) is diagnosed clinically using the West Haven criteria; precipitating factors (infection, GI bleeding, constipation, electrolyte disturbance, medications) must be identified and reversed urgently.
  • First-line treatment for overt HE is lactulose (titrate to 2–3 soft stools/day) plus rifaximin 550 mg BD (PBS Authority Required).
  • Uraemic encephalopathy presents with asterixis, confusion, seizures, and myoclonus; definitive management is renal replacement therapy (haemodialysis/peritoneal dialysis).
  • Coordinating with endocrinology, nephrology, hepatology, and neurology is essential; use GP Management Plans (MBS 721) and Team Care Arrangements (MBS 723) in the community.
  • Aboriginal and Torres Strait Islander Australians experience diabetes at 3–4 times the general rate and have higher rates of renal disease, making neurologic screening critical in these populations.
  • Glycaemic control (HbA1c target individualised ≤ 53 mmol/mol for most patients) is the single most effective intervention to prevent and slow progression of diabetic neuropathy.
  • Thiamine deficiency (alcoholic or nutritional) should be considered in all patients with hepatic or renal disease presenting with acute confusion—administer IV thiamine 300 mg immediately if suspected.
🎬 Neurologic Complications of Systemic Disease — clinical explainer

Introduction & Australian Epidemiology

Systemic diseases — particularly diabetes mellitus, chronic kidney disease (CKD), and chronic liver disease — are among the most prevalent conditions managed in Australian primary care and hospital settings. Each carries a substantial burden of neurologic morbidity that may present insidiously or as an acute neurologic emergency.

According to the Australian Institute of Health and Welfare (AIHW), an estimated 1.3 million Australians had diagnosed diabetes in 2023, with the true prevalence including undiagnosed cases estimated at over 1.7 million. Approximately 1.7 million Australians have indicators of CKD, and chronic liver disease accounts for over 7,000 deaths annually. The neurologic complications of these conditions contribute significantly to disability, hospital admissions, and healthcare costs.

This article provides a practical clinical guide for Australian primary care physicians, emergency clinicians, and specialists managing neurologic sequelae of systemic disease. It covers diabetes-related neuropathies (peripheral, autonomic, and focal), hepatic encephalopathy, and uraemic encephalopathy, with emphasis on screening, evidence-based management, and coordination of care within the Australian health system.

⚠️
Key population burden: Neuropathy is present in approximately 30–50 % of Australians with diabetes at the time of diagnosis of type 2 disease. CKD affects 1 in 10 Australian adults, and encephalopathy occurs in up to 30–45 % of patients with decompensated cirrhosis.
Neurologic Complications of Systemic Disease clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge — Neurologic Complications of Systemic Disease: pathophysiology, clinical clues, diagnosis, imaging, and management.
Neurologic Complications of Systemic Disease infographic, full size

Diabetes-Related Neurologic Issues

Diabetes mellitus is the most common cause of peripheral neuropathy worldwide and in Australia. Neurologic complications may affect somatic peripheral nerves (distal symmetric polyneuropathy, focal mononeuropathies, radiculoplexus neuropathy), autonomic nerves, and the central nervous system. Early identification and management of glycaemic control remain the cornerstone of prevention.

Peripheral Neuropathy — Screening and Diagnosis

Diabetic peripheral neuropathy (DPN) is predominantly a length-dependent, sensorimotor axonal polyneuropathy. The National Evidence-Based Guideline for Type 2 Diabetes (NHF/RACGP) recommends annual screening from the time of diagnosis of type 2 diabetes and from 5 years after diagnosis of type 1 diabetes.

🚨
Annual screening is mandatory: Every patient with diabetes should receive annual peripheral neurological assessment. Failure to screen is a common medicolegal and quality-of-care issue. Document assessment in the patient record and GP Management Plan (MBS Item 721/723).

Recommended screening tools in Australian primary care:

  • 10 g Semmes-Weinstein monofilament — tested at 3 plantar sites per foot (great toe, 1st metatarsal head, 5th metatarsal head); inability to detect = abnormal.
  • 128 Hz tuning fork — vibration sense at the dorsum of the great toe; diminished perception = abnormal.
  • Reflex hammer — ankle reflex (absent or diminished is significant when compared with knee reflex).
  • Neurothesiometer — quantitative vibration threshold testing, available in some specialist clinics.

If screening is abnormal, refer for nerve conduction studies (NCS) and electromyography (EMG) to confirm the diagnosis and characterise the neuropathy pattern. NCS are available through public hospital neurophysiology departments and private neurology practices (Medicare-rebated).

Autonomic Neuropathy

Diabetic autonomic neuropathy (DAN) affects cardiovascular, gastrointestinal, genitourinary, and sudomotor systems. Cardiovascular autonomic neuropathy (CAN) is the most clinically significant, associated with a 5-year mortality rate of up to 50 % in severe cases.

Screening for CAN:

  • Lying-to-standing blood pressure measurement — a sustained drop in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg on standing indicates orthostatic hypotension.
  • Heart rate response to deep breathing (heart rate variability).
  • Heart rate response to Valsalva manoeuvre.
  • 30:15 ratio (heart rate response to standing).

Clinical manifestations and management:

System Manifestation Management
Cardiovascular Orthostatic hypotension, resting tachycardia, exercise intolerance, silent myocardial ischaemia Graduated compression stockings; midodrine 2.5–10 mg PO TDS (specialist); fludrocortisone 50–200 µg PO OD (caution: hypertension, fluid overload); patient education re silent MI
Gastrointestinal Gastroparesis (nausea, vomiting, early satiety, erratic glucose control), constipation, diarrhoea Small frequent meals; metoclopramide 10 mg PO/IV TDS (short-term; risk of tardive dyskinesia); domperidone 10 mg PO TDS (PBS); erythromycin 200–250 mg PO QDS as prokinetic
Genitourinary Erectile dysfunction, neurogenic bladder, female sexual dysfunction Sildenafil 50–100 mg PO PRN (PBS Authority Required for diabetes); tadalafil 5–20 mg PO OD; intermittent self-catheterisation for neurogenic bladder
Sudomotor Anhidrosis of feet, gustatory sweating, heat intolerance Emollients for dry skin; glycopyrrolate cream for gustatory sweating; patient education on thermoregulation

Focal Mononeuropathies

Diabetic mononeuropathies include cranial nerve palsies (most commonly CN III, VI, VII) and peripheral nerve palsies (median nerve at the carpal tunnel, ulnar nerve at the elbow, common peroneal nerve at the fibular head). These are thought to result from ischaemic injury to the vasa nervorum.

  • CN III palsy — pupil-involving in 67 % of diabetic cases (pupil-sparing is the classic teaching, but up to one-third may have some pupillary involvement). Urgent MRI/MRA is recommended to exclude posterior communicating artery aneurysm, especially if pupil is involved or atypical features are present.
  • CN VII (Bell's palsy) — prednisolone 50 mg PO daily for 10 days if within 72 hours of onset (evidence from the BELL'S trial); eye protection with lubricant drops and tape at night.
  • Carpal tunnel syndrome — wrist splinting at night; corticosteroid injection (MBS-rebated); surgical decompression if refractory.
  • Most diabetic mononeuropathies recover spontaneously over 3–6 months; supportive care and optimisation of glycaemic control are essential.

Painful Diabetic Neuropathy — Pharmacotherapy

💊
Amitriptyline
Endep® · Tricyclic antidepressant
Adult dose 10–25 mg PO nocte, titrate by 10–25 mg every 1–2 weeks to 75–150 mg nocte
Paediatric dose Not recommended < 12 years for neuropathic pain
Renal adjustment Use with caution; no specific dose reduction but start at lowest dose in CKD
Hepatic adjustment Reduce dose or avoid in hepatic impairment
PBS status ✔ PBS General Benefit
💊
Duloxetine
Cymbalta® · SNRI
Adult dose 30 mg PO OD for 1 week, then 60 mg PO OD
Paediatric dose Not recommended < 18 years for neuropathic pain
Renal adjustment Avoid if eGFR < 30 mL/min/1.73 m²
Hepatic adjustment Contraindicated in hepatic impairment
PBS status ✔ PBS General Benefit
💊
Pregabalin
Lyrica® · Gabapentinoid
Adult dose 75 mg PO BD, titrate to 150–300 mg PO BD over 1–2 weeks
Paediatric dose Not established for neuropathic pain < 18 years
Renal adjustment eGFR 30–60: max 75–150 mg BD; eGFR 15–30: 25–75 mg OD; eGFR < 15: 25 mg OD
Hepatic adjustment No adjustment required
PBS status ✔ PBS Authority Required
💊
Gabapentin
Neurontin® · Gabapentinoid
Adult dose 300 mg PO OD (day 1), 300 mg BD (day 2), 300 mg TDS (day 3); titrate to 600 mg TDS as tolerated
Paediatric dose Not recommended < 12 years for neuropathic pain
Renal adjustment eGFR 30–59: max 300 mg BD; eGFR 15–29: 300 mg OD; eGFR < 15: 300 mg alternate days
Hepatic adjustment No adjustment required (not hepatically metabolised)
PBS status ✔ PBS Authority Required
ℹ️
Combination therapy: If monotherapy is inadequate after 4–8 weeks at therapeutic dose, consider combining agents from different classes (e.g., amitriptyline + pregabalin). Referral to a specialist pain service may be required. Capsaicin 8 % patch (Qutenza®) is available through specialist centres for localised neuropathic pain.

Renal & Hepatic Encephalopathy

Encephalopathy arising from renal failure (uraemic encephalopathy) and liver failure (hepatic encephalopathy) represents a critical neurologic complication of systemic organ failure. Both conditions are potentially reversible if precipitating factors are identified and managed promptly. These diagnoses require close coordination between general practice, emergency medicine, and specialty services (nephrology, hepatology, intensive care).

Hepatic Encephalopathy — Recognition and Classification

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities occurring in patients with liver dysfunction and/or portosystemic shunting. It is classified according to the West Haven criteria:

Grade I–II (Covert HE)
Mild Cognitive Impairment
Grade I: trivial lack of awareness, shortened attention span, altered sleep rhythm. Grade II: lethargy, apathy, disorientation to time, obvious personality change, inappropriate behaviour.
Setting: Outpatient / ward — may require specialist assessment with psychometric testing
Grade III (Overt HE)
Marked Confusion
Somnolence to semi-stupor, responsive to stimuli, marked confusion, gross disorientation, bizarre behaviour, asterixis present.
Setting: Inpatient — hepatology/ICU liaison, ammonia monitoring
Grade IV (Overt HE)
Coma
Comatose, unresponsive to verbal or painful stimuli; may have decerebrate or decorticate posturing. Cerebral oedema risk highest in acute liver failure.
Setting: ICU — intubation, ICP monitoring, transplant assessment
🚨
Life-threatening alert: Grade III–IV HE in the setting of acute liver failure carries mortality exceeding 80 % without liver transplant. Urgent transfer to a transplant centre (e.g., Royal Prince Alfred Hospital Sydney, Austin Health Melbourne, Princess Alexandra Hospital Brisbane, Sir Charles Gairdner Hospital Perth) with ICU-level care is essential.

Precipitating Factors of Hepatic Encephalopathy

Identifying and reversing precipitating factors is the most important initial management step. Up to 90 % of HE episodes have an identifiable precipitant.

Category Precipitant Investigation / Action
Infection Spontaneous bacterial peritonitis (SBP), UTI, pneumonia, cellulitis FBC, CRP, blood cultures, ascitic tap (PMN > 250/mm³ = SBP), urinalysis, CXR
GI bleeding Variceal haemorrhage, peptic ulcer Urgent endoscopy; resuscitation; ceftriaxone 1 g IV OD for SBP prophylaxis post-bleed
Constipation Increased ammonia absorption from the gut Lactulose 20–30 mL PO 2–4 hourly until bowel action, then titrate to 2–3 soft stools/day
Electrolyte disturbance Hypokalaemia, hyponatraemia, alkalosis U&E, VBG; correct electrolytes cautiously; avoid aggressive diuresis
Medications Opioids, benzodiazepines, sedatives, diuretic excess Medication review; stop sedatives; use flumazenil 200 µg IV if benzodiazepine-related (caution in chronic liver disease)
Renal impairment Hepatorenal syndrome, dehydration Volume assessment; renal function monitoring; nephrology consultation
Dietary protein excess High protein load increasing ammonia production Avoid protein restriction (outdated practice); ensure adequate protein 1.2–1.5 g/kg/day; vegetable and dairy protein preferred
Portosystemic shunt TIPS (transjugular intrahepatic portosystemic shunt) insertion TIPS embolisation or reduction if recurrent HE; hepatology/interventional radiology input

Hepatic Encephalopathy — Treatment

💊
Lactulose
Duphalac® · Osmotic laxative / ammonia-lowering
Adult dose Overt HE: 20–30 mL PO/NG every 2–4 hours until 2–3 soft stools/day, then 15–30 mL BD–TDS maintenance. Enema: 200 mL in 800 mL water PR retention for 30–60 min if unable to take PO.
Paediatric dose 1–3 mL/kg/day PO in divided doses; titrate to 2–3 soft stools/day
Renal adjustment No adjustment required; monitor for dehydration in CKD
Hepatic adjustment This is the primary indication — dose titrated to effect
PBS status ✔ PBS General Benefit
💊
Rifaximin
Xifaxan® · Non-absorbable antibiotic
Adult dose 550 mg PO BD
Paediatric dose Not established for HE in paediatrics
Renal adjustment No adjustment required (minimal systemic absorption)
Hepatic adjustment No dose adjustment; safety established in Child-Pugh A–C
PBS status ✔ PBS Authority Required (Specialist) — for prevention of recurrent overt HE

Uraemic Encephalopathy — Recognition

Uraemic encephalopathy occurs when the glomerular filtration rate falls sufficiently to allow accumulation of uraemic toxins. It is most commonly seen in patients with advanced CKD (eGFR < 15 mL/min/1.73 m²) or acute kidney injury, particularly when renal replacement therapy has not yet been initiated.

Clinical features (progressive):

  • Early: Fatigue, difficulty concentrating, irritability, sleep disturbance, nausea, anorexia.
  • Moderate: Asterixis (flapping tremor), confusion, disorientation, myoclonus, asterixis, hiccoughs, restlessness.
  • Severe: Seizures (generalised tonic-clonic), stupor, coma, decerebrate posturing.
⚠️
Distinguish from other causes: Always exclude other causes of encephalopathy including stroke, subdural haematoma, hypoglycaemia, sepsis, medication toxicity, Wernicke encephalopathy (thiamine deficiency), and hypertensive encephalopathy. Urgent CT brain should be performed if the presentation is atypical or focal neurologic signs are present.

Uraemic Encephalopathy — Management

  • Definitive treatment: Initiation or escalation of renal replacement therapy (intermittent haemodialysis or continuous renal replacement therapy in ICU). Peritoneal dialysis may be used if haemodialysis is not immediately available.
  • Seizure management: IV levetiracetam 1,000–1,500 mg is preferred (renally adjusted, minimal hepatic metabolism). Alternatively, IV valproate or phenytoin. Avoid benzodiazepines as first-line in the setting of uraemic encephalopathy due to prolonged clearance.
  • Electrolyte correction: Urgent treatment of hyperkalaemia (calcium gluconate 10 % 10–20 mL IV, insulin 10 units + 25 g dextrose 50 % IV, salbutamol 10–20 mg nebulised), metabolic acidosis (sodium bicarbonate if pH < 7.1), and hyperphosphataemia.
  • Avoid nephrotoxins: Cease or dose-adjust all renally cleared medications (use AMH/Clinical Pharmacology databases).
  • Thiamine 300 mg IV — administer immediately if there is any suspicion of nutritional deficiency (common in patients with poor oral intake, alcohol use, or prolonged vomiting).
ℹ️
Coordination tip: In rural and remote Australia, rapid access to nephrology and hepatology may be limited. Use the Royal Flying Doctor Service (RFDS) and state-based telehealth critical care networks (e.g., Emergency Telehealth Service WA, NETS Victoria) for advice on stabilisation and transfer. Document specialty consultations for medicolegal purposes.

Pathophysiology

Diabetic Neuropathy

Diabetic neuropathy results from a complex interplay of metabolic and vascular mechanisms:

  • Polyol pathway activation: Hyperglycaemia drives conversion of glucose to sorbitol by aldose reductase, causing intracellular osmotic stress, depletion of myoinositol and NADPH, and reduced Na⁺/K⁺-ATPase activity — all contributing to nerve conduction slowing and demyelination.
  • Advanced glycation end-products (AGEs): Non-enzymatic glycation of structural nerve proteins and basement membrane components leads to nerve fibre dysfunction, impaired axonal transport, and activation of the RAGE–NF-κB inflammatory cascade.
  • Oxidative and nitrosative stress: Excess mitochondrial superoxide production leads to DNA damage, poly(ADP-ribose) polymerase (PARP) activation, and endothelial dysfunction in the vasa nervorum, resulting in endoneurial hypoxia.
  • Protein kinase C (PKC) activation: Hyperglycaemia-derived diacylglycerol activates PKC, further impairing microvascular blood flow to peripheral nerves.
  • Autoimmune mechanisms: T-cell mediated immune injury to dorsal root ganglia may contribute to diabetic radiculoplexus neuropathy (diabetic amyotrophy).

Hepatic Encephalopathy

The pathogenesis of HE centres on the accumulation of ammonia (NH₃) and other neurotoxins (manganese, mercaptans, short-chain fatty acids, endogenous benzodiazepines) that are normally cleared by the liver:

  • Ammonia is produced by intestinal bacteria and enterocytes (glutaminase activity) and normally metabolised by hepatocytes via the urea cycle. In liver failure and portosystemic shunting, ammonia bypasses the liver and enters systemic circulation.
  • In the brain, astrocytes convert ammonia and glutamate to glutamine, an osmolyte that causes astrocyte swelling, cerebral oedema, and increased intracranial pressure (especially in acute liver failure).
  • Neuroinflammation amplifies ammonia toxicity: systemic inflammatory response syndrome (SIRS) and infection increase blood-brain barrier permeability and enhance cerebral ammonia uptake.
  • Changes in GABAergic, serotonergic, and dopaminergic neurotransmission contribute to the spectrum of neuropsychiatric manifestations.

Uraemic Encephalopathy

Uraemic encephalopathy is caused by the accumulation of uraemic toxins — small water-soluble molecules (urea, creatinine), middle molecules (β₂-microglobulin, parathyroid hormone), and protein-bound toxins (indoxyl sulphate, p-cresyl sulphate) — that are normally excreted by the kidneys:

  • These toxins disrupt the blood-brain barrier, alter neurotransmitter synthesis and release, impair neuronal energy metabolism, and promote oxidative stress.
  • Secondary hyperparathyroidism and calcium-phosphate dysregulation contribute to basal ganglia calcification and movement disorders.
  • Acidosis, hyponatraemia, and hyperosmolality further exacerbate cerebral dysfunction.

Clinical Presentation & Diagnostic Criteria

Diabetic Peripheral Neuropathy

The typical presentation is a length-dependent, symmetric, sensorimotor polyneuropathy:

  • Symptoms begin in the feet and progress proximally in a "stocking-and-glove" distribution.
  • Sensory: Numbness, tingling, burning pain (often worse at night), loss of proprioception, impaired balance.
  • Motor (late): Intrinsic foot muscle wasting, claw toes, pes cavus, foot deformity predisposing to ulceration.
  • Examination: Reduced/absent ankle reflexes, reduced vibration and monofilament sensation, impaired light touch and pinprick distally.

Diagnostic criteria (Toronto Consensus):

  • Symptoms or signs of peripheral neuropathy in a person with diabetes.
  • Abnormal nerve conduction studies (reduced amplitude, slowed conduction velocity, or both) — gold standard for confirming large-fibre neuropathy.
  • Exclusion of other causes (B12 deficiency, hypothyroidism, alcohol, CIDP, vasculitis) — requires basic blood work including B12, folate, TFTs, serum protein electrophoresis, ESR/CRP.

Hepatic Encephalopathy

Diagnosis is clinical, based on the West Haven criteria applied to patients with known liver disease or portosystemic shunting:

  • Asterixis (flapping tremor — positive in Grade II–III) — elicited by wrist extension with arms outstretched.
  • Psychometric testing (Number Connection Test A & B, Digit Symbol Test, line tracing) for covert HE detection.
  • Elevated serum ammonia — supportive but not diagnostic in isolation; levels correlate poorly with severity in chronic liver disease and may be normal in acute liver failure.
  • EEG showing triphasic waves (non-specific but supportive).
  • Exclude other causes: intracranial pathology (CT/MRI), sepsis, hypoglycaemia, Wernicke encephalopathy, drug intoxication, post-ictal state.

Uraemic Encephalopathy

Diagnosis requires a clinical–biochemical correlation:

  • Encephalopathy in the setting of severe renal impairment (eGFR typically < 15 mL/min/1.73 m² or acute kidney injury with rising creatinine and urea).
  • Elevated serum urea, creatinine, and potassium; metabolic acidosis.
  • Asterixis, myoclonus, and seizures (hyper-reflexia may be present).
  • Clinical improvement with renal replacement therapy is confirmatory.

Investigations

Essential
10 g Semmes-Weinstein monofilament testing
Bedside screening for loss of protective sensation in diabetic patients. Perform at 3 sites per foot annually. No Medicare item number (part of standard consultation).
Essential
128 Hz tuning fork (vibration perception)
Complementary bedside test for large-fibre function. Reduced vibration at the great toe is an early sign of DPN.
Available
Nerve conduction studies / EMG
Gold standard for confirming DPN. Available at public hospital neurophysiology departments and private neurology clinics. MBS Item 11000-series (consultation) and 11600-series (NCS). Referral required.
Available
Quantitative sensory testing (QST)
Thermal and vibration threshold testing using computerised devices. Available at select specialist centres. Useful for small-fibre neuropathy assessment.
Essential
Nerve-specific skin biopsy (intraepidermal nerve fibre density)
Gold standard for small-fibre neuropathy diagnosis. Punch biopsy (3 mm) from distal leg. Available through dermatology/pathology services at tertiary hospitals.
Essential
Lying-to-standing BP and heart rate
Screening for cardiovascular autonomic neuropathy. Measure BP supine after 5 min rest, then at 1 and 3 minutes after standing. Drop ≥ 20/10 mmHg systolic/diastolic = orthostatic hypotension.
Essential
Serum ammonia
Supportive investigation for hepatic encephalopathy. Must be collected on ice, transported immediately, and processed without delay (levels rise with tourniquet time and delay). Available in all hospital biochemistry labs.
Essential
Liver function tests, INR, albumin, bilirubin
Assess liver synthetic function and severity of liver disease (Child-Pugh, MELD scores).
Essential
U&E, creatinine, eGFR, BGL, FBC, CRP, blood cultures
Screen for precipitants of HE and evaluate renal function. Identify infection, electrolyte disturbance, and renal impairment contributing to encephalopathy.
Available
CT brain (non-contrast)
Rule out intracranial pathology (haemorrhage, mass lesion) before attributing encephalopathy to metabolic causes. Available 24/7 in metropolitan and major regional hospitals. MBS Item 56000-series.
Referral
Psychometric testing (Number Connection Test, Psychometric Hepatic Encephalopathy Score)
For diagnosis of covert hepatic encephalopathy. Performed by hepatology/neurology teams. Refer patients with unexplained cognitive decline and known liver disease.
Available
Abdominal ultrasound / Doppler
Assess liver architecture, portal hypertension, ascites, and portosystemic shunting. Available in most hospitals and private radiology. MBS Item 55000-series.

Risk Stratification & Severity Scoring

Diabetic Neuropathy Risk Stratification

Risk Category Findings Review Frequency Action
Low risk Normal sensation, normal pulses, no deformity Annual Routine foot care education; monofilament and pulse assessment
Moderate risk Loss of sensation (monofilament/vibration) OR absent pulses OR deformity Every 3–6 months Podiatry referral (MBS Item 10950); appropriate footwear; foot self-care education
High risk Loss of sensation + absent pulses + deformity; or previous ulcer/amputation Every 1–3 months Urgent podiatry; vascular assessment; multidisciplinary foot team; consider specialist footwear/insoles
Active problem Current ulcer, infection, gangrene, critical ischaemia Continuous Urgent referral to hospital-based multidisciplinary diabetic foot team; imaging (X-ray, MRI for osteomyelitis); IV antibiotics per eTG

Hepatic Encephalopathy Severity — West Haven Criteria & MELD Score

The MELD (Model for End-Stage Liver Disease) score is calculated as: MELD = 3.78 × ln(bilirubin mg/dL) + 11.2 × ln(INR) + 9.57 × ln(creatinine mg/dL) + 6.43. A MELD score ≥ 15 is a threshold for considering listing for liver transplant. Patients with recurrent overt HE despite optimal medical therapy and a MELD ≥ 15 should be referred for transplant assessment.

⚠️
Transplant referral threshold: Refer to a transplant centre when MELD ≥ 15, recurrent overt HE (≥ 2 episodes in 12 months despite lactulose + rifaximin), or any episode of Grade III–IV HE. Transplant centres in Australia: Royal Prince Alfred (Sydney), Austin Health (Melbourne), Princess Alexandra (Brisbane), Sir Charles Gairdner (Perth), Flinders Medical Centre (Adelaide), Royal Perth Hospital.
🖼️ Neurologic Complications of Systemic Disease — visual summary
Neurologic Complications of Systemic Disease visual summary infographic

Empirical / First-Line Therapy

Painful Diabetic Neuropathy — First-Line Approach

  1. Optimise glycaemic control — target HbA1c ≤ 53 mmol/mol (individualised; ≤ 48 mmol/mol if tolerated without significant hypoglycaemia). This is the only intervention proven to slow DPN progression in type 1 diabetes (DCCT/EDIC). Evidence in type 2 diabetes is less robust but supportive (UKPDS, ADVANCE).
  2. First-line analgesic: Amitriptyline 10–25 mg nocte (titrate to 75–150 mg), OR duloxetine 30 mg OD (titrate to 60 mg OD), OR pregabalin 75 mg BD (titrate to 300 mg BD). Choose based on comorbidities (duloxetine preferred if comorbid depression; amitriptyline if comorbid insomnia; pregabalin if TCA intolerant).
  3. Non-pharmacological: Foot care education, appropriate footwear, physiotherapy for balance and fall prevention, psychological support for chronic pain.

Hepatic Encephalopathy — First-Line Treatment

  1. Identify and treat precipitant — infection screen (ascitic tap, blood cultures, urinalysis, CXR); GI bleeding management; medication review; correct electrolytes.
  2. Lactulose 20–30 mL PO/NG every 2–4 hours until passage of 2–3 soft stools/day, then adjust to maintenance dose. Lactulose enema (200 mL in 800 mL water PR) if unable to take orally.
  3. Rifaximin 550 mg BD — add to lactulose for overt HE or if lactulose alone is insufficient. Reduces recurrence by approximately 50 % (Rifaximin Study, Bass et al. NEJM 2010).
  4. Nutrition: Do NOT restrict protein. Ensure 1.2–1.5 g protein/kg/day; small frequent meals; late evening snack (reduces overnight fasting catabolism). Vegetable and dairy protein may be better tolerated than animal protein.
  5. Avoid sedatives: Cease benzodiazepines, opioids, and antipsychotics wherever possible. If sedation absolutely required, use low-dose haloperidol (with ECG monitoring for QTc prolongation).

Uraemic Encephalopathy — First-Line Treatment

  1. Initiate or escalate renal replacement therapy — intermittent haemodialysis (standard) or continuous renal replacement therapy (CRRT) in haemodynamically unstable patients in ICU.
  2. Manage hyperkalaemia emergently: calcium gluconate 10 % 10–20 mL IV over 10 min (cardioprotection); insulin 10 units + 50 mL 50 % dextrose IV; salbutamol 10–20 mg nebulised; sodium bicarbonate 50–100 mmol IV if severe acidosis.
  3. Seizure management: IV levetiracetam 1,000–1,500 mg (preferred; renally adjusted) or sodium valproate 20 mg/kg IV loading. Avoid phenytoin (altered protein binding in uraemia). Lorazepam 4 mg IV for status epilepticus.
  4. Thiamine 300 mg IV — administer early if any nutritional concern.

Directed / Pathogen-Specific Therapy

Hepatic Encephalopathy — Second-Line and Refractory Therapy

  • L-ornithine L-aspartate (LOLA): Available in some formulations; may reduce ammonia levels. 10–20 g IV infusion over 4 hours. Not PBS-listed; used as adjunct in specialist settings.
  • IV albumin: 20 % human albumin solution 1–1.5 g/kg for 2–3 days in patients with decompensated cirrhosis and HE associated with SBP or large-volume paracentesis. Albumin improves effective arterial blood volume and reduces systemic inflammation.
  • Branch-chain amino acids (BCAAs): Oral BCAA supplementation may be considered in patients intolerant of dietary protein. Products available on special access schemes.
  • TIPS embolisation/reduction: For recurrent HE secondary to large portosystemic shunts (including post-TIPS). Interventional radiology procedure available at transplant-capable hospitals.
  • Prophylactic antibiotics for SBP: Norfloxacin 400 mg PO OD (PBS) or co-trimoxazole DS PO OD for patients with ascitic protein < 15 g/L or prior SBP. Ceftriaxone 1 g IV OD for 7 days for active SBP.

Diabetic Neuropathy — Disease-Modifying Therapies

  • Strict glycaemic control remains the only proven disease-modifying strategy. In type 1 diabetes, intensive insulin therapy reduced neuropathy by 60 % over 5 years (DCCT). In type 2 diabetes, multifactorial risk factor management (BP, lipids, glucose) is recommended (Steno-2 trial).
  • Aldose reductase inhibitors (e.g., epalrestat) — used in Japan; not currently available on the PBS in Australia. Limited evidence of clinical benefit.
  • Alpha-lipoic acid (thioctic acid): 600 mg IV OD for 3 weeks showed short-term symptom improvement in the SYDNEY and ALADIN trials. Oral supplementation (available OTC) has weaker evidence. Not PBS-listed.
  • Lifestyle modification: Smoking cessation, regular exercise (improves nerve perfusion and glycaemic control), weight management, and moderate alcohol intake are essential components.

Uraemic Encephalopathy — Directed Management

  • Dialysis adequacy optimisation: Target Kt/V ≥ 1.4 per haemodialysis session for patients on maintenance dialysis. Ensure regular dialysis review with nephrology (typically 3 sessions/week, 4–5 hours each).
  • Manage secondary hyperparathyroidism: Phosphate binders (calcium carbonate, sevelamer), calcitriol or alfacalcidol, cinacalcet (PBS Authority Required). Severe hyperparathyroidism (parathyroid hormone > 800 pg/mL) may require parathyroidectomy.
  • Erythropoiesis-stimulating agents (ESAs): Epoetin alfa (Eprex®) or darbepoetin alfa (Aranesp®) for renal anaemia (target Hb 100–120 g/L). Correcting anaemia may improve cognitive function. Both PBS-listed with Authority Required.

Monitoring

Diabetic Neuropathy Monitoring

Every visit
Foot inspection (skin integrity, calluses, ulcers, nail care); review footwear; assess pain severity (NRS 0–10) and impact on function.
Annually
Monofilament testing; vibration testing; ankle reflexes; pulse palpation (dorsalis pedis, posterior tibial); HbA1c, lipid profile, renal function. Document in GP Management Plan (MBS 721).
3–6 monthly (high risk)
Podiatry review; vascular assessment (ABI if indicated); wound review if active ulceration; specialist footwear review.
Per specialist direction
NCS/EMG to monitor progression; autonomic function testing; ophthalmology review (retinopathy often coexists with neuropathy).

Hepatic Encephalopathy Monitoring

During acute admission
Serial neurologic assessment (GCS, West Haven grade, asterixis) every 4–6 hours; serum ammonia every 12–24 hours (trend more useful than absolute value); U&E, LFTs daily; fluid balance; stool chart (lactulose titration target: 2–3 soft stools/day).
Post-discharge (first 4 weeks)
GP review within 7 days; confirm lactulose/rifaximin adherence and dose; review precipitant resolution (e.g., SBP treatment completion); ensure follow-up hepatology appointment.
Long-term
Hepatology review every 3–6 months; LFTs, INR, albumin, ammonia as indicated; covert HE screening annually; transplant listing review if MELD ≥ 15 or recurrent overt HE.

Uraemic Encephalopathy Monitoring

  • Pre-dialysis: U&E, creatinine, eGFR, calcium, phosphate, PTH every 1–3 months (CKD Stage 4–5); monthly if on dialysis.
  • Cognitive assessment at each nephrology visit (Mini-Mental State Examination or Montreal Cognitive Assessment).
  • Seizure threshold monitoring: ensure electrolytes (especially calcium, magnesium, sodium) are within range pre- and post-dialysis.
  • Dialysis adequacy: Kt/V measured monthly; ensure target Kt/V ≥ 1.4.

Special Populations

🤰

Pregnancy

Diabetic neuropathy in pregnancy
Gestational diabetes may unmask pre-existing neuropathy. Glycaemic targets are tighter in pregnancy (fasting ≤ 5.0 mmol/L, 1-hr post-prandial ≤ 7.4 mmol/L). Amitriptyline is Category B2 (avoid if possible); pregabalin is Category B3 (avoid). Duloxetine is Category C (avoid). Paracetamol and non-pharmacological approaches are preferred for pain management.
Hepatic encephalopathy in pregnancy
Acute fatty liver of pregnancy and HELLP syndrome can cause fulminant hepatic failure with encephalopathy. Immediate obstetric delivery is the definitive treatment. Lactulose is safe in pregnancy. Rifaximin — limited data; use only if benefits outweigh risks.
Uraemic encephalopathy in pregnancy
Pregnancy in women on dialysis carries high risk (fetal survival ~50 %). Intensify dialysis to 5–6 sessions/week. Nephrology and obstetric co-management at a tertiary centre is essential.
👶

Paediatrics

Diabetic neuropathy in children
Rare before puberty. Begin annual monofilament screening from age 10 years or 2 years after diagnosis of type 1 diabetes (whichever is later). Paediatric endocrinology referral for complex cases. NCS may require sedation in young children.
Hepatic encephalopathy in children
Most commonly seen in acute liver failure (viral hepatitis, drug-induced, Wilson disease, autoimmune hepatitis). Transfer to a paediatric liver transplant unit. Lactulose dose: 1–3 mL/kg/day PO. Avoid rifaximin in children < 12 years (limited safety data).
Uraemic encephalopathy in children
May present with irritability, poor feeding, seizures. Causes include haemolytic uraemic syndrome (HUS), congenital renal anomalies, and nephrotic syndrome complications. Paediatric nephrology referral is essential. Levetiracetam is preferred for seizures (10–15 mg/kg BD IV/PO).
👴

Elderly

Polypharmacy considerations
Elderly patients with diabetes, CKD, and liver disease often take multiple medications with CNS effects (opioids, benzodiazepines, anticholinergics). Conduct regular Home Medicines Reviews (MBS Item 900). Amitriptyline should be started at 5–10 mg in the elderly due to anticholinergic burden and fall risk.
Fall risk
Neuropathy (peripheral and autonomic) significantly increases fall risk in the elderly. Assess gait, balance, and orthostatic BP. Refer to physiotherapy and occupational therapy. Consider allied health Team Care Arrangement (MBS 723).
Cognitive overlap
Distinguish covert HE and uraemic encephalopathy from dementia and delirium in the elderly. Baseline cognitive assessment (MoCA) and serial assessment are essential. Age-appropriate HbA1c targets (≤ 64 mmol/mol for frail elderly) to avoid hypoglycaemia.
🫘

Renal Impairment

Medication adjustments
Gabapentin and pregabalin require significant dose reduction in CKD (see drug cards above). Amitriptyline: use lowest dose, monitor for anticholinergic toxicity. Duloxetine: avoid if eGFR < 30. Tramadol: reduce dose by 50 % if eGFR < 30, avoid if eGFR < 15. Metoclopramide: reduce dose if eGFR < 30.
Uraemic neuropathy vs diabetic neuropathy
Both commonly coexist. Uraemic neuropathy typically presents with a sensorimotor axonal polyneuropathy that improves with dialysis or transplantation. Dialysis may worsen carpal tunnel syndrome (amyloid deposition in long-term dialysis patients).
🫁

Hepatic Impairment

Medication safety
Patients with chronic liver disease are more susceptible to drug-induced encephalopathy. Avoid or reduce: benzodiazepines (contraindicated), opioids (use with extreme caution; fentanyl preferred over morphine), gabapentinoids (risk of sedation compounding HE). Paracetamol is safe up to 2 g/day in chronic liver disease (but avoid in acute liver failure).
Coagulopathy considerations
Patients with liver disease often have coagulopathy (elevated INR, thrombocytopenia). NCS/EMG and nerve/skin biopsy are generally safe; however, correct platelets to > 50 × 10⁹/L and INR < 1.5 if biopsy is planned. Vitamin K 10 mg IV/SC may correct some coagulopathy.
🛡️

Immunocompromised

Infection-related neuropathy
Immunocompromised patients (transplant recipients, HIV, chemotherapy) may develop neuropathy from CMV, VZV, HIV itself, or drug toxicity (e.g., vincristine, isoniazid, antiretrovirals). A broader differential is required; CSF analysis and MRI may be necessary.
HE in immunocompromised
Post-transplant patients on immunosuppression are at higher risk of infection-triggered HE. Maintain a high index of suspicion for SBP and other infections. Calcineurin inhibitors (tacrolimus, cyclosporine) can cause neurotoxicity — check drug levels and distinguish from HE.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Diabetes prevalence
Aboriginal and Torres Strait Islander Australians experience type 2 diabetes at 3–4 times the rate of non-Indigenous Australians (AIHW 2023). Diabetes-related complications, including neuropathy, are more prevalent and often present at a younger age. The onset of type 2 diabetes in ATSI populations frequently occurs before age 40, meaning neuropathy may develop during working-age years, compounding socioeconomic disadvantage.
Foot health and neuropathy
Rates of diabetes-related lower limb amputation are 3–6 times higher in ATSI Australians compared with non-Indigenous Australians. Barriers include limited access to podiatry services in remote communities, culturally inappropriate footwear, and delayed presentation of foot ulcers. Ring the Alarm — the national Indigenous foot complications program — provides resources and training for Aboriginal Health Workers to conduct foot screening.
Kidney disease burden
ATSI Australians have 2–3 times the rate of CKD compared with non-Indigenous Australians. Rates of end-stage kidney disease requiring dialysis are particularly high in remote communities (Northern Territory, Far North Queensland, Western Desert). Uraemic encephalopathy may occur due to delayed access to dialysis. The Purple House (Alice Springs) and other community-controlled dialysis services aim to keep people on country while receiving treatment.
Liver disease burden
Hepatitis B prevalence is significantly higher in ATSI communities (particularly in the Northern Territory). Hepatitis C, alcohol-related liver disease, and non-alcoholic fatty liver disease are also disproportionately represented. Early vaccination (hepatitis B) and antiviral treatment (hepatitis C — PBS-listed direct-acting antivirals) are essential prevention strategies for hepatic encephalopathy.
Remote and rural access
Specialist neurology, nephrology, and hepatology services are concentrated in metropolitan centres. Aboriginal and Torres Strait Islander people in remote areas may have to travel hundreds of kilometres for NCS, specialist review, or dialysis. Telehealth (Medicare Benefits Schedule telehealth items), RFDS, and visiting specialist outreach programs are critical to closing this gap. Aboriginal Health Workers and Aboriginal Community Controlled Health Organisations (ACCHOs) should be involved in care planning from the outset.
Cultural safety
Ensure culturally safe communication: use plain language, involve family and community where appropriate, and be aware of cultural obligations (e.g., sorry business). The Australian Charter of Healthcare Rights applies equally to all patients. Yarning-based approaches to health education can improve engagement and self-management of chronic disease and its neurologic complications.
Health checks and screening
Aboriginal and Torres Strait Islander health assessments (MBS Item 715) provide a funded opportunity for annual comprehensive assessment including diabetic neuropathy screening, renal function monitoring, and cognitive assessment. Ensure these are utilised. Closing the Gap PBS co-payment reforms (scripts ≤ $7.70 for concession holders, free for some) should improve medication access for neuropathic pain and encephalopathy prophylaxis.

Quick Reference — Common Clinical Scenarios

Painful diabetic neuropathy
Amitriptyline 25–75 mg nocte OR duloxetine 60 mg OD OR pregabalin 150 mg BD
Ongoing — review at 4–8 weeks for efficacy
Optimise HbA1c; foot care education; podiatry referral
Overt hepatic encephalopathy (Grade II–III)
Lactulose 20–30 mL PO/NG 2–4 hourly + rifaximin 550 mg BD
Acute: until improvement. Maintenance: ongoing
Identify and treat precipitant; ascitic tap; avoid sedatives
Uraemic encephalopathy with seizures
Levetiracetam 1,000–1,500 mg IV (renally adjusted) + urgent dialysis
Acute; seizures may recur until dialysis established
Correct hyperkalaemia; thiamine 300 mg IV; nephrology consult
Diabetic CN III palsy
Observation + optimise glycaemic control
Usually resolves in 3–6 months
MRI if pupil involved or atypical features; neurology referral
Orthostatic hypotension (diabetic autonomic neuropathy)
Compression stockings; midodrine 2.5–10 mg TDS (specialist)
Ongoing; monitor BP lying and standing
Review antihypertensives; slow positional changes; high-salt diet caution in CKD
SBP prophylaxis post-variceal bleed
Ceftriaxone 1 g IV OD for 7 days
7 days
Then switch to norfloxacin 400 mg PO OD for secondary prophylaxis
📊 Neurologic Complications of Systemic Disease — slide deck

Open slides PDF in new tab

📚 References

  1. 1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154.
  2. 2. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293.
  3. 3. Royal Australian College of General Practitioners (RACGP). Management of type 2 diabetes: A handbook for general practice. Melbourne: RACGP; 2020.
  4. 4. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–735.
  5. 5. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081.
  6. 6. Australian Institute of Health and Welfare (AIHW). Diabetes in Australia. AIHW; 2023. Available at: www.aihw.gov.au.
  7. 7. Australian Institute of Health and Welfare (AIHW). Chronic kidney disease in Aboriginal and Torres Strait Islander people. AIHW; 2023.
  8. 8. National Health and Medical Research Council (NHMRC). National evidence-based guideline for diagnosis, prevention and management of chronic kidney disease in Australia. Canberra: NHMRC; 2012.
  9. 9. Gruen RL, Bailie RS, Bailie RS, et al. Improving delivery of care for diabetic foot disease in Indigenous Australians. Med J Aust. 2006;185(1):15–18.
  10. 10. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986.
  11. 11. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes (Steno-2 trial). N Engl J Med. 2003;348(5):383–393.
  12. 12. Gines P, Angeli P, Lenz K, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397–417.
  13. 13. Lemberg A, Fernández MA, Galimberti RL. Neurological complications of chronic kidney disease. In: Handbook of Clinical Neurology. Vol 119. Elsevier; 2013:297–310.
  14. 14. RHDAustralia (ARF/RHD Australia). Recommendations for rheumatic fever and rheumatic heart disease. Darwin: Menzies School of Health Research; 2020. [ATSI healthcare reference for chronic disease management in Indigenous populations].
  15. 15. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.